Safety of enzalutamide in patients with metastatic castration‐resistant prostate cancer previously treated with docetaxel: Expanded access in North America

BACKGROUND: The open‐label, single‐arm enzalutamide expanded access program (EAP) in the United States and Canada evaluated the safety of enzalutamide in patients with metastatic castration‐resistant prostate cancer (mCRPC) who had previously received docetaxel. METHODS: Patients (n = 507) received...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Prostate
Main Authors: Joshua, Anthony M., Shore, Neal D., Saad, Fred, Chi, Kim N., Olsson, Carl A., Emmenegger, Urban, Scholz, Mark, Berry, William, Mukherjee, Som D., Winquist, Eric, Haas, Naomi B., Foley, Margaret A., Dmuchowski, Carl, Perabo, Frank, Hirmand, Mohammad, Hasabou, Nahla, Rathkopf, Dana
Formato: Artigo
Idioma:Inglês
Publicado em: John Wiley and Sons Inc. 2015
Assuntos:
Original Articles
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5024054/
https://ncbi.nlm.nih.gov/pubmed/25683285
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/pros.22965
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados